Proteon logo     Print Page | Close Window

SEC Filings

S-1
PROTEON THERAPEUTICS INC filed this Form S-1 on 09/16/2014
Entire Document
 

 

(b)                                 any damage, destruction or loss, whether or not covered by insurance, that would have a Material Adverse Effect;

 

(c)                                  any waiver or compromise by the Company of a valuable right or of a material debt owed to it;

 

(d)                                 any satisfaction or discharge of any lien, claim, or encumbrance or payment of any obligation by the Company, except in the ordinary course of business and the satisfaction or discharge of which would not have a Material Adverse Effect;

 

(e)                                  any material change to a material contract or agreement by which the Company or any of its assets is bound or subject;

 

(f)                                   any material change in any compensation arrangement or agreement with any employee, officer, director or stockholder;

 

(g)                                  any resignation or termination of employment of any officer or Key Employee of the Company, or of a consultant of the Company that would have a Material Adverse Effect;

 

(h)                                 any mortgage, pledge, transfer of a security interest in, or lien, created by the Company, with respect to any of its material properties or assets, except liens for taxes not yet due or payable and liens that arise in the ordinary course of business and do not materially impair the Company’s ownership or use of such property or assets and except for any encumbrances contemplated or created by the terms of the Option Agreement;

 

(i)                                     any loans or guarantees made by the Company to or for the benefit of its employees, officers or directors, or any members of their immediate families, other than travel advances and other advances made in the ordinary course of its business;

 

(j)                                    any declaration, setting aside or payment or other distribution in respect of any of the Company’s capital stock, or any direct or indirect redemption, purchase, or other acquisition of any of such stock by the Company;

 

(k)                                 any sale, assignment or transfer of any Company Intellectual Property that could reasonably be expected to result in a Material Adverse Effect;

 

(l)                                     receipt of notice that there has been a loss of, or material order cancellation by, any major customer of the Company;

 

(m)                             to the Company’s knowledge, any other event or condition of any character, other than events affecting the economy or the Company’s industry generally,  that could reasonably be expected to result in a Material Adverse Effect; or

 

(n)                                 any arrangement or commitment by the Company to do any of the things described in this Section 3.15.

 

3.16.                     Employee Matters.

 

30